- Home
- CVKD vs SCNX Comparison
CVKD vs SCNX Comparison
Compare CVKD & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | SCNX |
|---|---|---|
| Founded | 2022 | 2010 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 18.4M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CVKD | SCNX |
|---|---|---|
| Price | $5.78 | $0.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | 53.0K | ★ 1.5M |
| Earning Date | 03-12-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $653,391.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 207.88 |
| 52 Week Low | $5.34 | $0.42 |
| 52 Week High | $22.90 | $3.70 |
Technical Indicators
Market Signals| Indicator | CVKD | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.